Adaptimmune Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy ADAP

*Your capital is at risk

$0.0549

+0 (+0%)

At Close: Feb 20, 2026

Currently predicting for Wed, 17 Jun 2026

ADAP Live board

Community Bull/Bear

Target Next close

Join the ADAP prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

ADAP Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For ADAP

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

ADAP Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT ADAPTIMMUNE THERAPEUTICS PLC

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.84	4.82%	Jun 11
EAT $140.46	11.23%	Jun 05
TPR $140.47	7.49%	Jun 04
LITE $905.00	5.77%	Jun 01
W WCLD $27.34	12.84%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by